Aneurysmal subarachnoid hemorrhage is a disorder that is characterized by loss of consciousness, sudden severe headache, epileptic seizures, and neurological symptoms such as hemisensory or motor symptoms and dysphagia. The disease can be diagnosed by blood count test, urea and electrolytes test, serum glucose test, chest radiography, lumbar puncture, and computed tomography. The complications associated with aneurysmal subarachnoid haemorrhage include hydrocephalus, seizures, hyponatremia, immediate cerebral ischemia, and cardiopulmonary dysfunction. It has been observed that one in four people having sudden severe headache is found to be suspected with aneurysmal subarachnoid hemorrhage. The Göteborg University is in the process of developing OSU 6162 as a dopamine D2 receptor modulator for the treatment of aneurysmal subarachnoid hemorrhage. The Radboud University is in the process of developing deferoxamine as an iron chelating agent for the treatment of aneurysmal subarachnoid hemorrhage. Some of the universities and companies having the pipeline of aneurysmal subarachnoid hemorrhage include Thomas Jefferson University, Edge Therapeutics, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.